Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB +2.25%34 3-Year EPS without NRI Growth Rate is 44.80% as of Jun. 2026, which is 34% above its 10-year median of 33.45. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,162 Biotechnology companies, Solid Biosciences ranks better than 80.9% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 44.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 39.20% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 16.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Solid Biosciences was 44.80% per year. The lowest was -89.60% per year. And the median was 33.45% per year.
Solid Biosciences (NAS:SLDB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Solid Biosciences 3-Year EPS without NRI Growth Rate Related Terms
SLDB vs MNPR, DSGN, CLYM: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Solid Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solid Biosciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solid Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Solid Biosciences's 3-Year EPS without NRI Growth Rate falls into.
Solid Biosciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 44.80% mean?
Solid Biosciences (SLDB) has a 3-Year EPS without NRI Growth Rate of 44.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Solid Biosciences and its competitors. This is 34% above median its historical median of 33.45. According to the industry distribution chart, Solid Biosciences ranks #222 out of 1162 companies in the Biotechnology industry, placing it in the top 19.1%.
Is Solid Biosciences' 3-Year EPS without NRI Growth Rate too high?
Solid Biosciences' current 3-Year EPS without NRI Growth Rate of 44.80% is 34% above median its 10-year median of 33.45. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Solid Biosciences' value of 44.80% is 176.5% above this industry median. Based on the distribution chart, Solid Biosciences ranks #222 out of 1162 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' 3-Year EPS without NRI Growth Rate compare to MNPR and DSGN?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #222 out of 1162 companies for 3-Year EPS without NRI Growth Rate. This places Solid Biosciences in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Solid Biosciences' value of 44.80% is 176.5% above this benchmark. While the company's 10-year median is 33.45 vs. the industry median of 16.20, Solid Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solid Biosciences's current 3-Year EPS without NRI Growth Rate of 44.80% is 176.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Solid Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current 3-Year EPS without NRI Growth Rate is 44.80%, which is 34% above median its own 10-year median of 33.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current 3-Year EPS without NRI Growth Rate of 44.80%. The current 3-Year EPS without NRI Growth Rate is 44.80%, which is 34% above median its 10-year median of 33.45 and 176.5% above the Biotechnology industry median of 16.20. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current 3-Year EPS without NRI Growth Rate is 44.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
